Catalyst Brief

← Calendar

Readoutin 165d

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — SKB264

Phase 3 primary completion: A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer.

Date
May 2027
Type
Readout
Indication
Non-Small Cell Lung Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

  1. Dec2026
  2. Nov2026